Protara Therapeutics, Inc.
Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biopharmaceutical company developing therapies for cancer and rare diseases. Its pipeline includes TARA-002, an investigational cell therapy based on the immunopotentiator OK-432, and IV Choline Chloride, an investigational therapy for patients receiving… From the company’s description.
In fiscal 2025, Protara Therapeutics, Inc. reported a net loss of $57.44M. Operations used $56.37M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Protara Therapeutics, Inc. does
In the company’s own words
Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biopharmaceutical company developing therapies for cancer and rare diseases. Its pipeline includes TARA-002, an investigational cell therapy based on the immunopotentiator OK-432, and IV Choline Chloride, an investigational therapy for patients receiving parenteral support. The company is studying TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, including in pediatric patients; IV Choline Chloride is being developed as a source of choline for patients who cannot obtain adequate nutrition orally or enterally. TARA-002 is based on the same bacterial master cell bank as Picibanil, the OK-432 brand marketed in Japan, and Protara holds worldwide rights to TARA-002 excluding Japan and Taiwan. The company’s programs are in clinical development, and it has not generated product-sales revenue. For fiscal 2025, Protara reported no revenue. Its website is https://www.protaratx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1359931
- SIC
- 2836
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Protara Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Protara Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Protara Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Protara Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Protara Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”